ArticleESMO open2021
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center.
Article in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes.International journal of surgery (London, England) · 2025Pooled it
- Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- Large Language Models in Multidisciplinary Decision-Making for Hepatopancreatobiliary Oncology: Retrospective Comparative Feasibility Study.Journal of medical Internet research · 2026Article
- Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care.Updates in surgery · 2026Article
- CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation.Cancer cell international · 2025Article
- Late-stage hepatoid adenocarcinoma of the pancreatic head with a long survival after surgery: a case report.Journal of medical case reports · 2025Article
- Use and utility of endocrine multidisciplinary tumour board: an appraisal from a tertiary centre.Frontiers in endocrinology · 2025Article
- Imaging-Based Disease Assessment and Management Recommendations: Impact of Multidisciplinary Sarcoma Tumor Board.Cancers · 2024Article
- Article
- Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.Skeletal radiology · 2024Article
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.Journal of neuro-oncology · 2024Article
- Adherence to interdisciplinary tumor board recommendations as an expression of quality-assured patient care: results of a bicentric German analysis.Journal of cancer research and clinical oncology · 2023Article
- Building Team Medicine in the Management of CNS Metastases.Journal of clinical medicine · 2023Article
- The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience.Frontiers in surgery · 2023Article
- Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms.Abdominal radiology (New York) · 2022Article
- Implementation of a virtual multicenter gastrointestinal tumor board to reduce cancer disparities in Argentina.World journal of clinical oncology · 2022Review
- Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers.Updates in surgery · 2022Article
- Neuro-Oncology Multidisciplinary Tumor Board: The Point of View of the Neuroradiologist.Journal of personalized medicine · 2022Article
- From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care.Frontiers in oncology · 2022Article
- The impact of a multidisciplinary team approach on the management of focal pancreatic lesions: a single tertiary center experience.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe implementation of multidisciplinary tumor board (MDTB) meetings significantly ameliorated the management of oncological diseases. However, few evidences are currently present on their impact on pancreatic cancer (PC) management. The aim of this study was to evaluate the impact of the MDTB on PC diagnosis, resectability and tumor response to oncological treatment compared with indications before discussion. PATIENTS AND
methodsAll patients with a suspected or proven diagnosis of PC presented at the MDTB from 2017 to 2019 were included in the study. Changes of diagnosis, resectability and tumor response to oncological/radiation treatment between pre- and post-MDTB discussion were analyzed.
resultsA total of 438 cases were included in the study: 249 (56.8%) were presented as new diagnoses, 148 (33.8%) for resectability assessment and 41 (9.4%) for tumor response evaluation to oncological treatment. MDTB discussion led to a change in diagnosis in 54/249 cases (21.7%), with a consequent treatment strategy variation in 36 cases (14.5%). Change in resectability was documented in 44/148 cases (29.7%), with the highest discrepancy for borderline lesions. The treatment strategy was thus modified in 27 patients (18.2%). The MDTB brought a modification in the tumor response assessment in 6/41 cases (14.6%), with a consequent protocol modification in four (9.8%) cases.
conclusionsMDTB discussion significantly impacts on PC management, especially in high-volume centers, with consistent variations in terms of diagnosis, resectability and tumor response assessment compared with indications before discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.